Simon Schwartz Navarro Senior scientist and advisor with specific interest in Nanomedicine and Advanced Therapies applied to unmet clinical needs. I am also acting as strategy coordinator to facilitate programs and initiatives that foster innovation in new treatments and diagnostic tools. Instituciones de las que forman parte Investigador/a principal Bioquímica Clínica, Vehiculización de Fármacos y Terapia Vall Hebron Institut de Recerca Cap de Secció Bioquímica Serveis transversals LinkedIn Twitter Orcid Simon Schwartz Navarro LinkedIn Twitter Orcid Instituciones de las que forman parte Investigador/a principal Bioquímica Clínica, Vehiculización de Fármacos y Terapia Vall Hebron Institut de Recerca Cap de Secció Bioquímica Serveis transversals Senior scientist and advisor with specific interest in Nanomedicine and Advanced Therapies applied to unmet clinical needs. I am also acting as strategy coordinator to facilitate programs and initiatives that foster innovation in new treatments and diagnostic tools.
Senior research of the clinical biochemistry - drug delivery and therapy group at VHIR and Strategy director of biobanking and biomodels at Vall d'hebron Campus. President of the European Society of Nanomedicine and Executive Board member of the International Society of Nanomedicine. Former director general of the Blood and Tissue Banc of Catalonia. Former director of CIBBIM-Nanomedicine. Former scientific associate director of CIBER-BBN and coordinator of technology transfer. Former director assistance of translational research at VHIR. H-index of 48, with more that 120 high impact publications, 19 transferred patents and several EU granted projects. Co-founder of 3 biotech companies (i.e, Bsure Medical ltd). Science Advisor of the European Nanomedicine Characterization Laboratory (EU-NCL). Member of the editorial Board of Precision Nanomedicine, J. Nanotechnology and of J. of Nanotheranostics. Former editorial Board member of Eur. J. Nanomedicine and Nanomedicine-NBM. Exper member of the nanomedicine group at EMA.
Proyectos Desenvolupament d¿assaigs preclínics de nanosistemes per estudis clínics amb aplicació en càncer ductal pancreàtic. IP: Simon Schwartz Navarro Colaboradores: Miriam Izquierdo Sans Entidad financiadora: Generalitat de Catalunya - Departament de Salut Financiación: 67280.97 Referencia: SLT006/17/00270 Duración: 01/03/2018 - 14/05/2021 Terapia combinada mediante nuevos nanoconjugados terapéuticos contra Células Madre Tumorales en tumores de mamas triple negativos IP: Simon Schwartz Navarro Colaboradores: Laura García Latorre, Joaquin Seras Franzoso, Terapia combinada mediante nuevos nanoconjugados terapéuticos contra Células Madre Tumorales en tumores de mamas triple negativo, Diana Fernandes de Rafael Entidad financiadora: Instituto de Salud Carlos III Financiación: 123420 Referencia: PI17/02242 Duración: 01/01/2018 - 31/12/2020 Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease IP: - Colaboradores: Simon Schwartz Navarro, Sandra Mancilla Zamora, Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease Entidad financiadora: EUROPEAN COMMISSION Financiación: 266300.8 Referencia: SMART4FABRY_H2020NMBP2016 Duración: 01/01/2017 - 31/12/2020 (Nano) systems with active targeting to sensitize colorectal cancer stem cells to anti-tumoral treatment Target4Cancer IP: Simon Schwartz Navarro Colaboradores: Laura García Latorre, Joaquin Seras Franzoso, Diana Fernandes de Rafael Entidad financiadora: Instituto de Salud Carlos III Financiación: 143385 Referencia: AC15/00092 Duración: 01/01/2016 - 30/09/2019 Paginación Primera página « Página anterior ‹ … Página 3 Página 4 Página actual 5 Página 6 Página 7 … Siguiente página › Última página »
